Roche Holding stock: Oddo BHF lifts target for Roche Holding stock to CHF 440

Published on 10/21/2026 at 15:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche reports third-quarter sales on October 22, 2026. Roche Holding stock costs EUR 421.23 at Lang & Schwarz on October 21, 2026.

Analyst target and reporting date

Oddo BHF raised its Roche target from CHF 300.00 to CHF 440.00 on October 20, 2026.
Roche will publish third-quarter sales on October 22, 2026, before the Swiss market opens.
Roche Holding stock costs EUR 421.23 at Lang & Schwarz on October 21, 2026 at 3:02 p.m. CEST.
Core earnings per share rose 11.00 percent to CHF 19.46 in fiscal year 2025.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Oddo BHF raised its Roche Holding price target from CHF 300.00 to CHF 440.00 and upgraded the rating from Underperform to Outperform on October 20, 2026, Yahoo Finance reported. Roche Holding stock was trading at EUR 421.23 at Lang & Schwarz on October 21, 2026 at 3:02 p.m. CEST.

What changed in the analyst view?

Oddo BHF's revised target is CHF 140.00 above its earlier level, while the new rating marks a shift from Underperform to Outperform. Yahoo Finance linked the more positive view to Roche's diversified portfolio and limited exposure to generic medicines, while also noting questions around oncology and neurology programs.

Sales update arrives October 22

Roche is scheduled to publish third-quarter sales before the Swiss Stock Exchange opens on October 22, 2026, with the release planned for 7:00 a.m. CEST. The company will then hold a presentation and question-and-answer session at 2:00 p.m. CEST, according to Roche.

Roche enters the update with scale

Roche said its core earnings per share increased 11.00 percent to CHF 19.46 in fiscal year 2025, measured at constant exchange rates. The company also reported that 39.00 million patients received Roche medicines and that customers received 31.00 billion diagnostic tests during fiscal year 2025, giving the upcoming sales release a broad operating backdrop.

How does the counter-view look?

RBC Capital maintained an Outperform rating and a CHF 400.00 target on October 19, 2026, while its third-quarter revenue forecast stood 2.70 percent above consensus, according to MarketScreener. The difference between CHF 400.00 and CHF 440.00 shows how widely analyst views currently span ahead of the sales update.

The stock at Lang and Schwarz

Roche Holding stock was trading at EUR 421.23 at Lang & Schwarz on October 21, 2026 at 3:02 p.m. CEST. The next measurable company catalyst is the third-quarter sales publication on October 22, 2026.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.